CombinatoRx's CRx-170 misses endpoint

CRXX's CRx-170 missed the primary endpoint of change in circulating monocyte CD163 in a Phase II trial to treat asthma. The compound met the secondary endpoint of FEV1, with a 6% improvement from base...